Mindray reports 6.00 percent revenue growth: Mindray stock awaits October 30 results

Published on 10/21/2026 at 11:27 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

International revenue rose 13.67 percent to CNY 9.471 billion in first-half 2026. For Mindray stock, Q3 results are due October 30, 2026.

Revenue growth and reporting date

First-half revenue reached CNY 17.747 billion on October 19, 2026, up 6.00 percent.
International revenue rose 13.67 percent to CNY 9.471 billion in the first half of 2026.
Third-quarter results are scheduled for October 30, 2026.

Mindray, CNE100003G67, Illustration mit AI erstellt.

Mindray (ISIN CNE100003G67) reported first-half 2026 revenue of CNY 17.747 billion, up 6.00 percent from the same period a year earlier. The figures, reported by iNEWS on October 20, 2026, show a recovery in sales but continued pressure on profitability.

International sales lead recovery

International revenue was CNY 9.471 billion in the first half of 2026, an increase of 13.67 percent, and represented 53 percent of group revenue. iMedia reported on October 19, 2026, that international sales had become Mindray's largest revenue source.

The comparison with profit is less favorable. Net profit attributable to shareholders fell 5.37 percent to CNY 4.797 billion in the first half, according to iNEWS. The divergence makes margin recovery and foreign-exchange effects central issues for the next report.

What does the overseas mix mean?

The international mix gives Mindray a larger growth channel, but it also increases currency exposure. iMedia said exchange-rate effects reduced first-half profit by CNY 740 million, while revenue would have risen 8.16 percent on a neutral exchange-rate basis.

Emerging businesses supplied another quantified support. Revenue from minimally invasive surgery, interventional procedures and animal medicine reached CNY 3.11 billion in the first half, up 19.59 percent year over year, according to the same October 19 report.

Three dates shape the recovery

On September 3, 2026, Mindray announced a CNY 1.33 dividend per share; on September 30, 2026, the company announced third-quarter results for October 30; on October 19, 2026, coverage detailed first-half revenue of CNY 17.747 billion and international growth of 13.67 percent, according to Simply Wall St.

October 30 results set next test

The next scheduled date is October 30, 2026, when Mindray is due to report third-quarter results. Simply Wall St identifies the company as Shenzhen Mindray Bio-Medical Electronics and lists the Shenzhen Stock Exchange ticker 300760, while its current market capitalization was CNY 202.6 billion on October 19, 2026.

Business profile

Mindray develops patient monitoring, life-support, diagnostic and medical-imaging equipment. The company is listed in Shenzhen under ticker 300760, and its international expansion now supplies more than half of group revenue.